Nonetheless, our data suggest that targeting the beta-3 adrenergic receptor with agonist drugs may have clinical implications to improve treatment of patients with myeloproliferative neoplasms, and Nestin+ cells contribute to these events [51]. This evidence concerns the gene NES and myeloproliferative disorder.